ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2026
Comparative performance of the EQ-5D-5L, EQ-HWB, and PROMIS-10 in screening for history of anxiety and depression in the general adult population in 15 countries.
Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGeneric patient-reported outcome measures (PROMs) are increasingly being implemented in health systems for routine outcome measurement. Their ability to screen for anxiety and depression could serve as an added benefit. This study aims to assess the screening ability of selected EQ-5D-5L, EQ-HWB, and PROMIS-10 items for anxiety and depression, using self-reported diagnostic history of these conditions, relative to established PHQ-2 and GAD-2 screeners, in general adult populations across 15 countries.
methodsCross-sectional data from "EuroQol Data for Assessment of Population Health Needs and Instrument Evaluation (EQ-DAPHNIE)" project was used. The following countries were included in the analysis: Argentina, Australia, Brazil, Canada, Chile, China, France, Germany, Japan, Mexico, Netherlands, New Zealand, Spain, the United Kingdom (UK), and the United States (US). A sample size of 4500 was planned per country. Sample quotas for age, sex, income, and urban/rural area were based on census or national data in each country. The performance of specific mental health items of the EQ-5D-5L, EQ-Health and Wellbeing (EQ-HWB), Patient-Reported Outcomes Measurement Information System Scale v1.2 - Global Health (PROMIS-10), Generalized Anxiety Disorder 2-item questionnaire (GAD-2), and Patient Health Questionnaire 2-item version (PHQ-2) were compared to self-reported diagnostic history of anxiety or depression. Performance of EQ-5D-5L, EQ-HWB, PROMIS-10, GAD-2, and PHQ-2 in screening for anxiety and depression was evaluated using area under receiver operating curve (AUROC) analysis
resultsA total of 68,419 respondents from 15 countries completed surveys. Brazil had the highest percentage of self-reported anxiety diagnoses (29.6%). The US had the highest depression diagnoses (26.7%), anxiety or depression diagnoses (34.1%), and anxiety and depression diagnoses (20.9%). By contrast, China had the lowest percentage of diagnoses for depression (3.9%) and anxiety or depression (9.7%) and Japan the lowest for anxiety (3.7%) and anxiety and depression (2.1%). Across all countries, except China, the EQ-5D-5L anxiety/depression dimension performed the best in screening for all conditions (AUROC range: 0.76-0.88), followed by the PROMIS-10 emotional problems item (AUROC range: 0.75-0.84). All measures performed considerably lower in China (AUROC range: 0.65-0.75).
conclusionGeneric PROMs, like the EQ-5D-5L, EQ-HWB, and PROMIS-10 have potential added value as effective screening tools for anxiety and depression in the general adult population, as evidenced by their performance across multiple countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.